Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

Rhythm Pharmaceuticals (RYTM): Losses Widen, But 45.8% Revenue Growth Sets Up Profitability Narrative

Rhythm Pharmaceuticals (RYTM) reported widening losses, with net losses having grown at a rate of 18.8% per year over the past five years. Despite being unprofitable, the company commands a Price-To-Sales Ratio of 40x, outpacing both the US Biotechs industry average of 10.8x and the peer average of 17.9x, positioning its stock as highly valued on these multiples. On the growth front, forecasts point to revenue expanding at 45.8% per year and earnings projected to grow 70.56% per year, with...
TSX:WJX
TSX:WJXTrade Distributors

Wajax (TSX:WJX) Margin Contraction Challenges Value Narrative Despite Five-Year Earnings Growth

Wajax (TSX:WJX) reported net profit margins of 2.2%, down from 2.5% in the prior year, as the company faced a contraction in margin performance. Over the past twelve months, earnings growth turned negative, and revenue is projected to decline at a rate of 0.2% per year over the next three years. Still, Wajax has built a 3.7% annual earnings growth rate over the last five years, which highlights a longer-term trend of improvement despite recent setbacks. See our full analysis for Wajax. Up...
NasdaqGS:PRAA
NasdaqGS:PRAAConsumer Finance

PRA Group (PRAA): Persistent Losses Challenge Undervaluation Narrative Despite Low Price-To-Sales Ratio

PRA Group (PRAA) is currently unprofitable, with losses having grown at an average annual rate of 48.8% over the last five years. While revenue is projected to grow at 6.6% per year, this is slower than the broader US market’s pace of 10.5% per year. The company is expected to remain unprofitable for at least the next three years. Margins have seen no improvement over the past year, signaling that profitability remains a persistent challenge for investors considering this stock. See our full...